Detailed Narrative
Q3 FY26 Financial Performance Overview
Natco Pharma reported a consolidated total revenue of ₹705.4 crores for Q3 FY26, marking an 8.34% increase from ₹651.1 crores in Q3 FY25. The company achieved an EBITDA of ₹216.8 crores, translating to a healthy margin of 30.7%. Consolidated net profit for the quarter stood at ₹151.3 crores, reflecting a solid financial performance.
Adcock Ingram Contribution and Amortization Impact
The company's share of profit from its associated company, Adcock Ingram Holdings, for the period of November 10 to December 31, 2025, was ₹29.65 crores. After accounting for a one-time📎 amortization of ₹18.75 crores, the net profit reflection in Natco's financials was ₹10.9 crores. Management anticipates a recurring quarterly PAT addition of ₹35-40 crores from Adcock, with an annual amortization of ₹10-14 crores, or approximately ₹3 crores per quarter.
Semaglutide Launch Strategy and Market Outlook
Natco Pharma is preparing for the launch of semaglutide (Ozempic and Wegovy) in India, with Ozempic having received SEZ committee clearance and a license expected shortly. The fill-finish capacity for the Indian market is currently outsourced. Management expects the market to be highly competitive with many generics but aims for its domestic business, currently annualized at ₹450-460 crores, to grow by over 20% this year, primarily driven by semaglutide.
NCE Pipeline and eGenesis Investment
The company is actively pursuing five New Chemical Entity (NCE) ideas, with eGenesis (xenotransplantation using CRISPR-Cas9 technology) highlighted as the most exciting. Natco has invested $8 million in eGenesis, which aims to genetically modify pig organs for human transplantation. Management views this as a high-risk, disruptive technology with the potential for a 'home run' in 2-3 years if trials involving 25-30 patients demonstrate success, noting one patient has done well for 6 months and another is progressing positively.
Capital Allocation for Acquisitions and Geographical Expansion
With a net cash position of approximately ₹2,500 crores, Natco Pharma is prioritizing cash for large acquisitions rather than a share buyback. The company is actively pursuing 2-3 acquisition targets, aiming to close 1-2 in 2026, focusing on emerging markets and established brand businesses. Management believes opportunities outside India offer better returns and is building geographical footprints in Canada, US, Brazil, and South Africa, with Western Europe identified as a key market not yet fully present in.
R&D Strategy and Operational Efficiency
The R&D budget allocation was strategically managed in the September quarter, anticipating the decline in Revlimid contribution, with most R&D for the next few months already covered. While R&D spend typically hovers around 8% of sales, the company is recalibrating its approach, including exploring partnerships for complex generics to share expenditure and reduce risk, ensuring continued investment in its pipeline while maintaining momentum.
Manufacturing Plant Regulatory Updates
Natco Pharma provided updates on its four FDA-approved plants. The warning letter for the Kothur facility has been removed, and the Mekaguda plant received clearance after inspection this year. The Chennai plant was inspected this year and is awaiting classification, with observations deemed procedural, and classification expected within 30-40 days. The Vizag formulation facility is also due for an inspection this year, with the last inspection having occurred 2.5-3 years ago.